A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

October 11, 2024

Study Completion Date

October 11, 2024

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

Cendakimab

Specified dose on specified days

DRUG

CYP substrates

Specified dose on specified days

Trial Locations (12)

27710

Local Institution - 018, Durham

34452

Local Institution - 002, Inverness

43235

Local Institution - 012, Columbus

52242

Local Institution - 008, Iowa City

85715

Local Institution - 004, Tucson

90067

Local Institution - 001, Los Angeles

92103-5639

Local Institution - 022, San Diego

06010-5142

Local Institution - 016, Bristol

33144-2035

Local Institution - 010, Miami

33324-3345

Local Institution - 021, Plantation

60031-5711

Local Institution - 020, Gurnee

87106-4725

Local Institution - 003, Albuquerque

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY